LENSAR, Inc. (LNSR)
| Previous close | 3.3900 |
| Open | 3.5300 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.4101 - 3.9800 |
| 52-week range | 1.8000 - 5.3000 |
| Volume | |
| Avg. volume | 43,903 |
| Market cap | 43.53M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3100 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
Business WireLENSAR Reports First Quarter 2024 Results and Provides Business Update
ORLANDO, Fla., May 09, 2024--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2024 and provided an update on key operational initiatives.
Business WireLENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
ORLANDO, Fla., May 02, 2024--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s first quarter 2024 financial results will be released before market open on Thursday, May 9, 2024. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, May 9, 2024 to discuss the financial results and recent corporate highlights.
Business WireLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla., May 01, 2024--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company’s common stock. The options were granted as of May 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5
